An overview of daratumumab monotherapy for heavily treated multiple myeloma

Sagar Lonial

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA, summarises the potential of the anti-CD38 monoclonal antibody, daratumumab, as a novel, well-tolerated, single-agent therapy for patients with heavily treated multiple myeloma.

Share this video  
Multiple Myeloma
Daratumumab
EHA 2015
2nd June 2015
More from Sagar Lonial
Myeloma highlights from ASCO 2017
Final analysis of Panorama 1: Phase 3 trial of panobinostat for multiple myeloma
New targets in relapsed/refractory multiple myeloma patients
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals